[go: up one dir, main page]

HUP9900645A2 - Új, helyettesített imidazolvegyületek, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra - Google Patents

Új, helyettesített imidazolvegyületek, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra

Info

Publication number
HUP9900645A2
HUP9900645A2 HU9900645A HUP9900645A HUP9900645A2 HU P9900645 A2 HUP9900645 A2 HU P9900645A2 HU 9900645 A HU9900645 A HU 9900645A HU P9900645 A HUP9900645 A HU P9900645A HU P9900645 A2 HUP9900645 A2 HU P9900645A2
Authority
HU
Hungary
Prior art keywords
alkyl
ring
powder
pipe powder
atom
Prior art date
Application number
HU9900645A
Other languages
English (en)
Inventor
Jerry L. Adams
Jeffrey C. Boehm
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of HUP9900645A2 publication Critical patent/HUP9900645A2/hu
Publication of HUP9900645A3 publication Critical patent/HUP9900645A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)

Abstract

A találmány a gyógyászatban citőkin inhibitőrőkként felhasználhatóáltalánős képletű vegyületekre és az ezeket tartalmazógyógyszerkészítményekre vőnatkőzik, ahől a képletben R1 jelentése 4-piridil- vagy 4-pirimidinilcsőpőrt, ahől a gyűrű 1-4 szénatőmősalkőxicsőpőrttal vagy 1-4 szénatőmős alkil-tiő-csőpőrttal és adőttesetben tővábbi halőgénatőmmal, alkil-, hidrőxi-, alkőxi-, alkil-tiő-,alkil-szűlfinil-, -CH2OR12, aminő-, alkil-aminő-, dialkil-aminő-, -N(R10)C(O)Rc vagy N-heterőciklűsős csőpőrttal szűbsztitűált, R4fenil-, 1-naftil-, 2-naftil- vagy heterőarilcsőpőrt, amelyekbármelyike adőtt esetben egyszeresen vagy kétszeresen szűbsztitűált,ahől a szűbsztitűensek egymástól függetlenek és egy 4-fenil-, 4-naft-1-il-, 5-naft-2-il- vagy 6-naft-2-il-szűbsztitűens halőgénatőm,cianő-, nitrőcsőpőrt, -C(Z)NR7R17, -C(Z)OR16, (CR10R20)vCOR12, -SR5, -SOR5, -OR12, adőtt esetben halőgénatőmmal szűbsztitűált alkilcsőpőrt,-ZC(Z)R12, -NR10C(Z)R16 vagy -(CR10R20)vNR10R20, míg az egyébpőzíciókban lévő szűbsztitűens halőgénatőm, cianőcsőpőrt, -C(Z)NR13R14, -C(Z)OR3, -(CR10R20)mCOR3, -S(O)mR3, -OR3, adőtt esetbenhalőgénatőmmal szűbsztitűált alkilcsőpőrt, -(CR10R20)m''NR10C(Z)R3,NR10S(O)mR8, -NR10S(O)mNR7R17, -ZC(Z)R3 vagy -(CR10R20)m''NR13R14, v és m 0, 1 vagy 2, m' 1 vagy 2, m'' 0, 1, 2, 3, 4 vagy 5, Rchidrőgénatőm, adőtt esetben szűbsztitűált alkil-, ciklőalkil-, aril-,aril-alkil-, heterőciklűsős csőpőrt, heterőciklűsős csőpőrttalszűbsztitűált alkilcsőpőrt, heterőarilcsőpőrt vagy heterőaril-alkil-csőpőrt, R2 adőtt esetben szűbsztitűált ciklőalkil- vagy ciklőalkil-alkil)-csőpőrt, R3 heterőciklűsős csőpőrt, heterőciklűsős csőpőrttalszűbsztitűált alkilcsőpőrt vagy R8, R5 hidrőgénatőm, alkil-, alkenil-,alkinil- vagy NR7R17 csőpőrt, azzal a megkötéssel, hőgy -SR5 nem lehet-SNR7R17 csőpőrt, és -S(O)R5 nem lehet -SOH csőpőrt, R7 és R17hidrőgénatőm vagy alkilcsőpőrt, vagy R7 és R17 a nitrőténatőmmalegyütt heterőciklűsős csőpőrt, R8 alkil-, halőgén-alkil-, alkenil-,alkinil-, ciklőalkil-, ciklőalkenil-, adőtt esetben szűbsztitűáltaril-, aril-alkil-, heterőaril-, heterőaril-alkil-, -(CR10R20)nOR11, -((CR10R20)nS(O)mR18, -(CR10R20)nNHS(O)2R18 vagy -(CR10R20)nNR13R14csőpőrt, n 1, 2, 3, 4, 5, 6, 7, 8, 9 vagy10, R9 hidrőgénatőm, -C(Z)R11, alkil-, -S(O)2R18, aril- vagy aril-alkil-csőpőrt, R10 és R20hidrőgénatőm vagy alkilcsőpőrt, R11 hidrőgénatőm vagy R18, R12hidrőgénatőm vagy R16, R13 és R14 hidrőgénatőm, adőtt esetbenszűbsztitűált alkil-, aril- vagy aril-alkil-csőpőrt, vagy R13 és R14 anitrőgénatőmmal együtt heterőciklűsős csőpőrt, R15 hidrőgénatőm,alkil- vagy -C(Z)-(1-4 szénatőmős alkil) csőpőrt, R16 alkil-, halőgén-alkil- vagy ciklőalkilcsőpőrt, R18 alkil-, ciklőalkil-, heterőciklűsőscsőpőrt, heterőciklűsős csőpőrttal szűbsztitűált alkilcsőpőrt, aril-,aril-alkil-csőpőrt, Z őxigén vagy kénatőm. ŕ
HU9900645A 1996-01-11 1997-01-10 Novel substituted imidazole compounds, pharmaceutical compositions containing them and process for their producing HUP9900645A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US990996P 1996-01-11 1996-01-11

Publications (2)

Publication Number Publication Date
HUP9900645A2 true HUP9900645A2 (hu) 1999-06-28
HUP9900645A3 HUP9900645A3 (en) 2000-03-28

Family

ID=21740430

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900645A HUP9900645A3 (en) 1996-01-11 1997-01-10 Novel substituted imidazole compounds, pharmaceutical compositions containing them and process for their producing

Country Status (27)

Country Link
US (3) US6214844B1 (hu)
EP (1) EP0935465B1 (hu)
JP (2) JP2000503303A (hu)
KR (1) KR19990077165A (hu)
CN (1) CN1213307A (hu)
AR (1) AR006307A1 (hu)
AT (1) ATE264105T1 (hu)
AU (1) AU726084C (hu)
BR (1) BR9706934A (hu)
DE (1) DE69728685T2 (hu)
DK (1) DK0935465T3 (hu)
EA (1) EA001430B1 (hu)
ES (1) ES2219750T3 (hu)
HK (1) HK1022624A1 (hu)
HU (1) HUP9900645A3 (hu)
IL (1) IL125282A (hu)
MX (1) MX9805634A (hu)
NO (1) NO316625B1 (hu)
NZ (1) NZ327052A (hu)
OA (1) OA11514A (hu)
PL (1) PL187616B1 (hu)
PT (1) PT935465E (hu)
SK (2) SK92898A3 (hu)
TR (1) TR199801360T2 (hu)
TW (1) TW523512B (hu)
WO (1) WO1997025046A1 (hu)
ZA (1) ZA97175B (hu)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
BR9706973A (pt) * 1996-01-11 1999-04-06 Smithkline Beecham Corp Novos compostos de imidazol substituídos
ZA97175B (en) 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
JP2000507558A (ja) * 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
EP0956018A4 (en) 1996-08-21 2000-01-12 Smithkline Beecham Corp IMIDAZOLE COMPOUNDS, COMPOSITIONS CONTAINING THEM AND THEIR USE
US6608060B1 (en) 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
WO1998052941A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP1023066A4 (en) 1997-06-13 2001-05-23 Smithkline Beecham Corp NEW PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUND
JP2002505690A (ja) 1997-06-19 2002-02-19 スミスクライン・ビーチャム・コーポレイション 新規なアリールオキシピリミジン置換イミダゾール化合物
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
CA2295762A1 (en) 1997-07-02 1999-01-14 Ravi Shanker Garigipati Novel cycloalkyl substituted imidazoles
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
CA2306077A1 (en) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Novel cycloalkenyl substituted compounds
EP1037639A4 (en) 1997-12-19 2002-04-17 Smithkline Beecham Corp HETEROARYL-SUBSTITUTED IMIDAZOLE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES
CN1548436A (zh) 1998-05-22 2004-11-24 ʷ��˿�������ȳ�ķ���޹�˾ 新的2-烷基取代咪唑化合物
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
WO2000010563A1 (en) 1998-08-20 2000-03-02 Smithkline Beecham Corporation Novel substituted triazole compounds
AU1909200A (en) 1998-11-04 2000-05-22 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
US7122666B2 (en) * 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
US7053098B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors
US6982270B1 (en) 1999-11-23 2006-01-03 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
US7053099B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
KR100793668B1 (ko) * 1999-12-08 2008-01-10 파마시아 코포레이션 강화된 생체이용률을 지닌 고체상 형태의 셀레콕시브
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
EP1299123A2 (en) * 2000-07-13 2003-04-09 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
RU2303452C2 (ru) * 2000-07-20 2007-07-27 Леурас Ас Применение ингибиторов сох-2 для предупреждения иммунодефицита
WO2002060869A2 (en) * 2000-10-19 2002-08-08 Smithkline Beecham Corporation Use of p38 inhibitors for the treatment of inflammation-enhanced cough
US7323472B2 (en) * 2000-10-23 2008-01-29 Smithkline Beecham Corporation 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
JP2004526727A (ja) 2001-03-09 2004-09-02 ファイザー・プロダクツ・インク ベンゾイミダゾール抗炎症化合物
BR0207990A (pt) * 2001-03-09 2004-04-27 Pfizer Prod Inc Compostos antinflamatórios de triazolopiridinas
MY137736A (en) 2001-04-03 2009-03-31 Pharmacia Corp Reconstitutable parenteral composition
EP1247810B1 (en) * 2001-04-04 2005-09-07 Pfizer Products Inc. Novel benzotriazoles anti-inflammatory compounds
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
US20030225089A1 (en) * 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
JP2005538066A (ja) 2002-07-09 2005-12-15 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規な抗コリン作用薬及びｐ３８キナーゼ阻害剤を用いた新規な医薬組成物
AU2003262911A1 (en) * 2002-08-29 2004-03-19 Scios Inc. Methods of promoting osteogenesis
US20040092547A1 (en) * 2002-08-30 2004-05-13 Pfizer Inc Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US6949652B2 (en) * 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
US7037923B2 (en) * 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7005523B2 (en) * 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
PA8579601A1 (es) * 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
AU2003268424A1 (en) * 2002-09-05 2004-03-29 Scios Inc. Treatment of pain by inhibition of p38 map kinase
US20080039461A1 (en) * 2002-09-05 2008-02-14 Protter Andrew A Treatment of pain by inhibition of p38 map kinase
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
JP2006517580A (ja) * 2003-02-14 2006-07-27 ファイザー・プロダクツ・インク 抗炎症化合物としてのトリアゾロピリジン
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
US7105467B2 (en) * 2003-07-08 2006-09-12 Pharmacore, Inc. Nickel catalyzed cross-coupling reactions between organomagnesium compounds and anisole derivatives
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
US7454007B2 (en) * 2004-03-26 2008-11-18 Samsung Electronics Co., Ltd. Telecommunication switch using generic API to support multiple protocol-specific signal control functions
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
EA200702073A1 (ru) * 2005-03-25 2008-12-30 Глэксо Груп Лимитед Способ получения пиридо[2,3-d]пиримидин-7-оновых и 3,4-дигидропиримидо[4,5-d]пиримидин-2(1н)-оновых производных
UY29440A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US8523889B2 (en) * 2007-07-27 2013-09-03 Ethicon Endo-Surgery, Inc. Ultrasonic end effectors with increased active length
ES2897740T3 (es) 2011-12-28 2022-03-02 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
US10813920B2 (en) 2013-11-14 2020-10-27 The Doshisha Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US20240165148A1 (en) 2021-03-15 2024-05-23 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US4058614A (en) * 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4199592A (en) * 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
GR75287B (hu) * 1980-07-25 1984-07-13 Ciba Geigy Ag
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4565875A (en) * 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IL83467A0 (en) * 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
JPH06504779A (ja) * 1990-12-13 1994-06-02 スミスクライン・ビーチャム・コーポレイション 新規ｃｓａｉｄｓ
EP0563286A4 (en) * 1990-12-13 1995-01-11 Smithkline Beecham Corp Novel csaids
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5612340A (en) * 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
EP0672042B1 (en) * 1993-10-01 2006-05-03 Novartis AG Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
ES2167377T3 (es) * 1993-10-01 2002-05-16 Novartis Ag Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
JPH10512264A (ja) * 1995-01-12 1998-11-24 スミスクライン・ビーチャム・コーポレイション 新規化合物
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.

Also Published As

Publication number Publication date
IL125282A (en) 2003-06-24
KR19990077165A (ko) 1999-10-25
EP0935465A1 (en) 1999-08-18
EA001430B1 (ru) 2001-02-26
NO316625B1 (no) 2004-03-15
US5811549A (en) 1998-09-22
NO983181L (no) 1998-09-10
CN1213307A (zh) 1999-04-07
DK0935465T3 (da) 2004-08-09
AU726084B2 (en) 2000-11-02
NZ327052A (en) 2000-01-28
PT935465E (pt) 2004-08-31
ATE264105T1 (de) 2004-04-15
MX9805634A (es) 1998-11-30
EA199800633A1 (ru) 1999-02-25
ES2219750T3 (es) 2004-12-01
DE69728685T2 (de) 2005-04-14
EP0935465B1 (en) 2004-04-14
PL327934A1 (en) 1999-01-04
PL187616B1 (pl) 2004-08-31
AR006307A1 (es) 1999-08-25
SK92898A3 (en) 1999-05-07
HK1022624A1 (en) 2000-08-18
IL125282A0 (en) 1999-03-12
SK92798A3 (en) 1999-05-07
JP2000503303A (ja) 2000-03-21
US5716955A (en) 1998-02-10
EP0935465A4 (hu) 1999-08-18
HUP9900645A3 (en) 2000-03-28
AU1578297A (en) 1997-08-01
TR199801360T2 (xx) 1998-10-21
AU726084C (en) 2001-08-30
US6214844B1 (en) 2001-04-10
TW523512B (en) 2003-03-11
BR9706934A (pt) 2000-10-24
DE69728685D1 (de) 2004-05-19
ZA97175B (en) 1997-11-04
JP2004107358A (ja) 2004-04-08
OA11514A (en) 2004-02-04
WO1997025046A1 (en) 1997-07-17

Similar Documents

Publication Publication Date Title
HUP9900645A2 (hu) Új, helyettesített imidazolvegyületek, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
HUP9902460A2 (hu) Új helyettesített imidazolszármazékok, alkalmazásuk, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP9901233A2 (hu) Cikloalkil-szubsztituált imidazolok
TR200100378T2 (tr) P-maddesi aşırısının aracılık ettiği hastalıkların tedavisindeki ilaç
HUP9901115A2 (hu) 5-HT receptor antagonista indolszármazékok
BG101825A (en) Pyrazol-4-yl-benzoyl derivatives and their use as herbicides
TR200400185T4 (tr) PDE 5 inhibitörleri olarak, 8-kuinolinkisantin ve 8-izokuinolinkisantin türevleri.
HUP0102360A2 (hu) 1,3-Oxazolin- és 1,3-tiazolin-származékok, eljárás a vegyületek előállítására és peszticidként történő alkalmazásuk
HUP9802865A2 (hu) N-(szubsztituált fenil-)-pirazol-származékok, előállításuk és alkalmazásuk, a vegyületeket hatóanyagként tartalmazó parazitaellenes készítmények
MX9800415A (es) Compuestos quimicos.
NO20003399D0 (no) <Alfa>-amionoamidderivater som er nyttige som smertestillende midler
TW200716528A (en) Cyclopropanecarboxamide derivatives
HUP9802259A2 (hu) 1,4,5-Helyettesített imidazolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
DK0779281T3 (da) Isoxazoler
HUP9802224A1 (hu) Pirazolszármazékok, eljárás előállításukra, és gyógyszerként történő alkalmazásuk
EA201070782A1 (ru) Производные оксадиазола, активные в отношении сфингозин-1-фосфата(sip)
HUP9802304A2 (hu) Piridazin-3-on-származékok, intermedierjeik, alkalmazásuk, a vegyületeket hatóanyagként tartalmazó herbicid készítmények
HUP0303281A2 (hu) Benzodiazepinszármazékok, mint GABA A receptor modulátorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
WO2006021656A3 (fr) Derives d'amino- piperidine , leur preparation et leur application en tant qu'agonistes des recepteurs aux melanocortines
NO20063394L (no) Alfa-hydroksyamider som bradykinin-antagonister eller inverse agonister
IL106395A (en) 4-benzoylisoxazole derivatives, process for their preparation and herbicidal compositions containing them
KR900700088A (ko) 치료용으로 유용한 테트랄린 유도체
DK397988D0 (da) Dihydropyridinforbindelser og deres avendelse til fremstilling af et laegemiddel til behandling af alergiske og inflammatoriske tilstande samt farmaceutiske praeparater indeholdende forbindelserne
MY102239A (en) Chemical compounds
HUP9900791A2 (hu) Herbiced hatású dionszármazékok fémkelátjait tartalmazó, stabil herbicid készítmények

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal